

#12



Atty. Dkt. No. SALK 2270-5  
(088802-5212)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: EVANS, et al.

Title: NOVEL STEROID-ACTIVATED  
NUCLEAR RECEPTORS AND USES  
THEREFOR

Appl. No.: 10/081,555

Filing Date: February 20, 2002

Examiner: Unknown

Art Unit: Unknown

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

GERMAINE SARDA

(Printed Name)

Germaine Sarda

(Signature)

November 19, 2002

(Date of Deposit)

**AMENDMENT**

Commissioner for Patents  
Box Missing Parts  
Washington, D.C. 20231

Sir:

In response to the Office communication dated September 20, 2002 (Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures), please consider the following amendments and remarks.

**In the Specification**

Please replace paragraphs [0061] and [0062] with the following amended paragraphs [0061] and [0062]. A marked-up version of these paragraphs, showing the changes made, is also provided herewith as Appendix A.

-- [0061] Examples of response elements suitable for use in practice of the invention. methods can be selected from the following:

In re application of  
Evans et al.  
Appl. No. 10/081,555  
Page 2

Atty. Dkt. No. SALK 2270-5  
(088802-5212)

DR-3,4,5 = AGGTCA $n$ AGGTCA, wherein n is 3, 4, or 5 (SEQ ID NOS: 44, 45 and 46);

$\beta$ DR-3,4,5 = AGTTCAN $n$ TGAAC $t$ , wherein n is 3, 4 or 5 (SEQ ID NOS: 47, 48 and 22); and

IR-6 = TGAAC $t$ N $n$ AGGTCA, wherein n is 6 (SEQ ID NO: 23), and the like.

[0062] Those of skill in the art will recognize that any combination of nucleotides can be used to make up the 3, 4, 5, or 6 nucleotide space between the repeated half sites (*i.e.*, Nn in SEQ ID NOS: 44, 45, 46, 22 or 23). --

#### **Sequence Listing**

Applicants respectfully submit a computer readable form (CRF) and a paper copy of the sequence listing herewith. A statement to support filing and submission in accordance with 37 C.F.R. 1.821-1.825 is also enclosed herewith.